Want to see AU:OSL full AI Analyst Report?
OSL Stock Chart & Stats
AU$1.16
-AU$0.14(-11.97%)
At close: 4:00 PM EDT
AU$1.16
-AU$0.14(-11.97%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$1.69
Previous CloseN/A
Volume503.64K
Average Volume (3M)108.61K
Market Cap
AU$29.91M
Enterprise ValueAU$12.61M
Total Cash (Recent Filing)AU$6.48M
Total Debt (Recent Filing)AU$14.78K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding36,703,940
10 Day Avg. Volume55,318
30 Day Avg. Volume108,612
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.22
Price to Sales (P/S)9.54
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$4.40M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue is accelerating, indicating increasing commercial activity and potential adoption of the company’s therapy. Although growth starts from a small base, sustained expansion could improve operating leverage, broaden market reach, and support progress toward a more viable revenue platform.
Low Financial LeverageMinimal debt limits interest and refinancing pressure while preserving flexibility to direct resources toward product development, clinical evidence, regulatory approvals, and commercialization. This gives OncoSil greater resilience than a similarly loss-making business carrying substantial leverage.
Focused Oncology PlatformA focused device platform in interventional oncology gives the company a clear strategic direction around a defined clinical application. Concentrating development, evidence generation, approvals, and commercialization on this therapy can support specialized expertise and coherent resource allocation.
Bears Say
Persistent UnprofitabilityNegative gross profit and large operating losses show that current revenue does not yet cover the economics of the business. The company remains far from break-even, so durable earnings power depends on substantial scaling, improved margins, and tighter cost control.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business is consuming cash to support operations rather than funding itself internally. Without material improvement, continued funding will be needed, limiting strategic flexibility and increasing dependence on external capital.
Dilution RiskIf losses and cash burn continue, capital raising may become necessary to finance operations and development. Fluctuating equity levels indicate potential dilution for existing holders, while repeated funding needs could constrain capital allocation and reduce the benefit of future revenue growth.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.37 and its highest was AU$1.69 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$29.91M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 130 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Aug 28, 2026. The company reported -AU$0.236 earnings per share for the quarter.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 36,703,940 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.236 in its last earnings report. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 86%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.92%
12-Months-Change
Fundamentals
Return on Equity
-245.90%
Trailing 12-Months
Asset Growth
44.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Technical Analysis
Polynovo
―
Impedimed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―